# Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease

> **NCT07224490** · PHASE1 · RECRUITING · sponsor: **Stephanie B. Seminara, MD** · enrollment: 40 (estimated)

## Conditions studied

- Reproductive Disorder
- Neurodegeneration
- SARS-CoV 2

## Interventions

- **DRUG:** Kisspeptin 112-121

## Key facts

- **NCT ID:** NCT07224490
- **Lead sponsor:** Stephanie B. Seminara, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-10
- **Primary completion:** 2030-05
- **Final completion:** 2030-05
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07224490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07224490, "Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07224490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*